Fencabtagene autoleucel

芬卡基奥仑赛

Report date: 2024/06/11 20:00:08

Base Information

Drug NameFencabtagene autoleucel

Drug Alias NameTAC01-HER2

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTriumvira Immunologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTriumvira Immunologics Inc

Active IndicationsN/A

Inactive IndicationsStomach Neoplasms

Other Information

ATC CodeN/A